EI
TGTX icon

EAM Investors’s TG Therapeutics TGTX Stock Holding History

EAM Investors’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-77,823
Closed -$2.8M – 336
2025
Q2 		$2.8M Sell
77,823
-52,247
-40% -$1.95M 0.42% 118
2025
Q1 		$5.13M Buy
130,070
+1,147
+0.9% +$38.6K 0.89% 9
2024
Q4 		$3.88M Sell
128,923
-47,036
-27% -$1.35M 0.55% 91
2024
Q3 		$4.12M Buy
+175,959
New +$3.84M 0.62% 66
2023
Q3 		– Sell
-84,552
Closed -$2.1M – 376
2023
Q2 		$2.1M Sell
84,552
-55,483
-40% -$1.43M 0.39% 99
2023
Q1 		$2.11M Sell
140,035
-25,412
-15% -$386K 0.41% 93
2022
Q4 		$1.96M Buy
+165,447
New +$1.2M 0.41% 95
2021
Q2 		– Sell
-58,675
Closed -$2.83M – 435
2021
Q1 		$2.83M Sell
58,675
-6,570
-10% -$316K 0.43% 56
2020
Q4 		$3.39M Sell
65,245
-31,235
-32% -$1.06M 0.56% 32
2020
Q3 		$2.58M Sell
96,480
-59,604
-38% -$1.37M 0.61% 32
2020
Q2 		$3.04M Buy
+156,084
New +$2.51M 0.67% 24
2017
Q4 		– Sell
-308,120
Closed -$3.65M – 345
2017
Q3 		$3.65M Sell
308,120
-5,067
-2% -$57.7K 0.49% 56
2017
Q2 		$3.15M Sell
313,187
-17,763
-5% -$199K 0.52% 61
2017
Q1 		$3.86M Buy
+330,950
New +$2.38M 0.61% 28
2015
Q3 		– Sell
-410,689
Closed -$6.81M – 337
2015
Q2 		$6.81M Buy
410,689
+8,814
+2% +$140K 0.8% 5
2015
Q1 		$6.22M Sell
401,875
-28,752
-7% -$435K 0.72% 5
2014
Q4 		$6.82M Buy
430,627
+176,734
+70% +$2.3M 0.95% 2
2014
Q3 		$2.71M Buy
253,893
+117,501
+86% +$1.09M 0.55% 28
2014
Q2 		$1.28M Buy
+136,392
New +$872K 0.24% 219

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

EAM Investors's TGTX Position: Q3 2025 in Review

EAM Investors sold out of TG Therapeutics (TGTX) in Q3 2025, closing a stake of 77,823 shares — an estimated $2.8M sold.

EAM Investors first reported a position in TGTX in Q2 2014 and held it in 19 quarters. The position peaked at $6.82M in Q4 2014. 354 funds tracked by Wall St. Rank hold TGTX as of Q3 2025.

  • EAM Investors reported no remaining TG Therapeutics position as of Q3 2025 after selling out during the quarter.
  • EAM Investors sold 77,823 TG Therapeutics shares in Q3 2025, an estimated $2.8M.
  • EAM Investors first reported a position in TG Therapeutics in Q2 2014 and held it in 19 quarters.
  • EAM Investors's TG Therapeutics position peaked at $6.82M in Q4 2014.
  • 354 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2025.

Based on EAM Investors's 13F filing for Q3 2025, filed 14 Nov 2025.